Neurobloc® became available in the U.K. in 2001. Its alternative name is Clostridium botulinum type – B neurotoxin complex and it is manufactured from purified type – B neurotoxin produced by the bacteria Clostridium botulinum.
Neurobloc works by temporarily preventing the release of acetycholine from sympathetic nerve terminals. It should be administered by trained members of the medical profession only and is used to treat Cervical dystonia.
The following should avoid using NeuroBloc:
Individuals with a known hypersensitivity to any component of the formulation.
Patients who have generalised disorders of muscle activity (e.g. myasthenia gravis).
Patients where aminoglycoside antibiotics or spectinomycin are already being used or are likely to be used.
Patients who have bleeding disorders of any type.
Pregnant or lactating women.